94 related articles for article (PubMed ID: 9600339)
1. Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents.
Dosch J; Christmann M; Kaina B
Carcinogenesis; 1998 Apr; 19(4):567-73. PubMed ID: 9600339
[TBL] [Abstract][Full Text] [Related]
2. Mismatch repair and differential sensitivity of mouse and human cells to methylating agents.
Humbert O; Fiumicino S; Aquilina G; Branch P; Oda S; Zijno A; Karran P; Bignami M
Carcinogenesis; 1999 Feb; 20(2):205-14. PubMed ID: 10069455
[TBL] [Abstract][Full Text] [Related]
3. Highly elevated ultraviolet-induced mutation frequency in isolated Chinese hamster cell lines defective in nucleotide excision repair and mismatch repair proteins.
Nara K; Nagashima F; Yasui A
Cancer Res; 2001 Jan; 61(1):50-2. PubMed ID: 11196196
[TBL] [Abstract][Full Text] [Related]
4. Methylation tolerance in mismatch repair proficient cells with low MSH2 protein level.
Claij N; Te Riele H
Oncogene; 2002 Apr; 21(18):2873-9. PubMed ID: 11973647
[TBL] [Abstract][Full Text] [Related]
5. 1,2-Dimethylhydrazine-induced colon carcinoma and lymphoma in msh2(-/-) mice.
Colussi C; Fiumicino S; Giuliani A; Rosini S; Musiani P; Macrà C; Potten CS; Crescenzi M; Bignami M
J Natl Cancer Inst; 2001 Oct; 93(20):1534-40. PubMed ID: 11604476
[TBL] [Abstract][Full Text] [Related]
6. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
7. Mutator phenotype in Msh2-deficient murine embryonic fibroblasts.
Reitmair AH; Risley R; Bristow RG; Wilson T; Ganesh A; Jang A; Peacock J; Benchimol S; Hill RP; Mak TW; Fishel R; Meuth M
Cancer Res; 1997 Sep; 57(17):3765-71. PubMed ID: 9288785
[TBL] [Abstract][Full Text] [Related]
8. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
[TBL] [Abstract][Full Text] [Related]
9. Mismatch repair provokes chromosome aberrations in hamster cells treated with methylating agents or 6-thioguanine, but not with ethylating agents.
Armstrong MJ; Galloway SM
Mutat Res; 1997 Feb; 373(2):167-78. PubMed ID: 9042397
[TBL] [Abstract][Full Text] [Related]
10. Tissues of MSH2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent.
Andrew SE; McKinnon M; Cheng BS; Francis A; Penney J; Reitmair AH; Mak TW; Jirik FR
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):1126-30. PubMed ID: 9448296
[TBL] [Abstract][Full Text] [Related]
11. Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells.
Claij N; te Riele H
Oncogene; 2004 Jan; 23(1):260-6. PubMed ID: 14712231
[TBL] [Abstract][Full Text] [Related]
12. Repopulating defect of mismatch repair-deficient hematopoietic stem cells.
Reese JS; Liu L; Gerson SL
Blood; 2003 Sep; 102(5):1626-33. PubMed ID: 12730104
[TBL] [Abstract][Full Text] [Related]
13. DNA mismatch repair deficiency stimulates N-ethyl-N-nitrosourea-induced mutagenesis and lymphomagenesis.
Claij N; van der Wal A; Dekker M; Jansen L; te Riele H
Cancer Res; 2003 May; 63(9):2062-6. PubMed ID: 12727820
[TBL] [Abstract][Full Text] [Related]
14. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine.
Toft NJ; Winton DJ; Kelly J; Howard LA; Dekker M; te Riele H; Arends MJ; Wyllie AH; Margison GP; Clarke AR
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3911-5. PubMed ID: 10097137
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer.
de Wind N; Dekker M; Berns A; Radman M; te Riele H
Cell; 1995 Jul; 82(2):321-30. PubMed ID: 7628020
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents.
Bearzatto A; Szadkowski M; Macpherson P; Jiricny J; Karran P
Cancer Res; 2000 Jun; 60(12):3262-70. PubMed ID: 10866320
[TBL] [Abstract][Full Text] [Related]
17. The effect of Msh2 knockdown on methylating agent induced toxicity in DNA glycosylase deficient cells.
Cooley N; Elder RH; Povey AC
Toxicology; 2010 Jan; 268(1-2):111-7. PubMed ID: 20025921
[TBL] [Abstract][Full Text] [Related]
18. Molecular and cellular characterization of Mex-/methylation-resistant phenotype. Gene and cDNA cloning, serum dependence, and tumor suppression of transfectant strains.
Fritz G; Dosch J; Thielmann HW; Kaina B
J Biol Chem; 1993 Oct; 268(28):21102-12. PubMed ID: 8407947
[TBL] [Abstract][Full Text] [Related]
19. Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation.
DeWeese TL; Shipman JM; Larrier NA; Buckley NM; Kidd LR; Groopman JD; Cutler RG; te Riele H; Nelson WG
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11915-20. PubMed ID: 9751765
[TBL] [Abstract][Full Text] [Related]
20. Induction of c-fos, c-jun, junB and junD mRNA and AP-1 by alkylating mutagens in cells deficient and proficient for the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) and its relationship to cell death, mutation induction and chromosomal instability.
Dosch J; Kaina B
Oncogene; 1996 Nov; 13(9):1927-35. PubMed ID: 8934539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
